No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?

Objective pare the effects of metastasectomy combined with immunotherapy and metastasectomy alone in the treatment of patients with metastatic renal cell carcinoma. als and Methods l of 93 patients who had undergone metastasectomy were included in the study. Patients were categorized according to immunotherapy status, including the immunotherapy group (n = 70) and the no immunotherapy group (n = 23). s immunotherapy group, median overall survival was 56.1 months (95% confidence interval [CI] 34.1–78.2), whereas the no immunotherapy group reached a median overall survival of 21.3 months (95% CI 3.4–39.2), respectively. The 1, 3, and 5-year overall survival rates were calculated at 67.1% and 56.5%, 30.0% and 34.8%, and 7.1% and 19.0%, for the immunotherapy group and the no immunotherapy group, respectively (P = 1.000). When patients were stratified according to the time of metastasis, overall survival was not significantly different among the groups in patients with synchronous metastasis or in those with metachronous metastasis. Multivariate Cox proportional hazards model analysis showed that multiplicity of metastasis (odds ratio 3.68; 95% CI 1.85–7.34; P < 0.001) and metastatic sites (odds ratio 2.12; 95% CI 1.15–3.90; P = 0.016) were independent predictors of overall survival. sions asectomy combined with adjuvant immunotherapy did not result in a significantly higher overall survival rate as compared with metastasectomy alone. Our findings raise the question of “Is there a role of adjuvant immunotherapy after complete metastasectomy in patients with metastatic renal cell carcinoma?”